GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

AZD2389   Click here for help

GtoPdb Ligand ID: 13842

Synonyms: AZD-2389 | example 67 [WO2022130270A1]
Compound class: Synthetic organic
Comment: The chemical structure of AZD2389 was disclosed during the 'First Time disclosures' session at the ACS Spring 2025 meeting in San Diego [2]. This matches one of the compounds claimed in Astrazeneca's patent WO2022130270A1 [1]. AZD2389 is proposed to inhibit the prolyl endopeptidase activity of fibroblast activation protein (FAP; i.e. inhibition of cleavage of FGF21 and α2-antiplasmin/α2-AP), as a mechanism to treat liver fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) where elevated FAP expression drives pathogenic hepatic fibroblasts.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 123.33
Molecular weight 411.48
XLogP -0.85
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC2=NC=CC(=C2C=C1N3CCOCC3)C(=O)NCC(=O)N4CSC[C@H]4C#N
Isomeric SMILES O=C(CNC(=O)C1=C2C=C(C=CC2=NC=C1)N3CCOCC3)N4CSC[C@H]4C#N
InChI InChI=1S/C20H21N5O3S/c21-10-15-12-29-13-25(15)19(26)11-23-20(27)16-3-4-22-18-2-1-14(9-17(16)18)24-5-7-28-8-6-24/h1-4,9,15H,5-8,11-13H2,(H,23,27)/t15-/m1/s1
InChI Key GECJKRWOVGXGCO-OAHLLOKOSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Branalt J, Holm B, Johansson M, Karlsson O, Knerr DL, Nordqvist A, Sheppard RJ, Swanson M, Tomberg A. (2022)
N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides.
Patent number: WO2022130270A1. Assignee: Astrazeneca Ab. Priority date: 16/12/2021. Publication date: 23/06/2022.
2. Nordqvist A, Brånalt J, Winiwarter S, Petersen J, Eriksson AW, Liljeblad M, Janzén D, Miliotis T, Carlsson ET, Liu J et al.
AZD2389, a first in class candidate drug for the treatment of metabolic dysfunction-associated steatohepatitis.
Accessed on 03/04/2025. Modified on 03/04/2025. acs.digitellinc.com, https://acs.digitellinc.com/p/s/azd2389-a-first-in-class-candidate-drug-for-the-treatment-of-metabolic-dysfunction-associated-steatohepatitis-622940